244 results about "Psychiatric Disease" patented technology

A magnetic stimulation apparatus for central nervous system and circuit thereof and use of the apparatus and method of using the apparatus are shown. Controlling circuit design and outputting wave form signal to a drive power supply circuit enables the drive power supply circuit to output current of corresponding wave form to coils, and by means of the design of the shape, number of turns, size, interval of the coils, generates within a certain region inside the coils a desired time-variant magnetic field which is then applied to the brain of an animal or a human being so that the central nervous system can receive a wide area synergy magnetic stimulation with a precise wave form, high frequency or a combination of a plurality of frequency components, thus achieving the treatment of nervous and psychiatric diseases or brain function improvement in combination with behavior guidance, thought guidance, or psychological guidance.

Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.

The present invention pertains to compositions and methods for therapeutically and/or prophylactically treating patients with neurological, neurogenetic, or psychiatric diseases, disorders, conditions, or distress. Specifically, the present invention relates to the administration of compositions containing vitamins B₆ and E, magnesium oxide, essential fatty acids, and folate.

Compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia and manic or mixed episodes associated with bipolar I disorder with or without psychotic features is disclosed:

wherein R₁-R₈, G, N and A⁻ are as defined in the written description.

Exemplary method, system and computer-accessible medium can be provided for diagnosing at least one disease and/or a subtype within a disease. For example, it is possible to determine at least one region of interest, and obtain a plurality of data points associated with each of such region(s) of interest. It is also possible to identify a particular pattern of the data points across each of such region(s) of interest. Further, it is possible, e.g., using a computer arrangement, to determine a likelihood of the disease(s) and/or the subtype by comparing the particular pattern to at least one known pattern.

The present invention relates to a pharmaceutical composition comprising glycerol esters of a fatty acid, wherein the compositions are useful for the delivery of anti-psychotic drugs.

The present invention relates to an injectable, pharmaceutical composition comprising a C_1-6 alkyl ester of a C_10-20 fatty acid. In an embodiment, the fatty acid is ethyl oleate, isopropyl oleate, ethyl myristate, or isopropyl myristate. These compositions are useful for the delivery of anti-psychotic drugs.

The invention disclosed herein relates to methods and systems for modulating activity of a nervous system component. Neural pattern recognition is used to identify a neurological and/or psychiatric disease or disorder based on input generated by electric signals indicative of the subject's brain activity. In an embodiment, the method comprises receiving an input from one or more sensors, each sensor configured to sense a particular characteristic indicative of a neurological or psychiatric condition or state; developing treatment parameters based on the input received from the one or more sensors; and generating neural modulation signals for delivery to a nervous system component through one or more output devices in accordance with one or more developed treatment parameters.

The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy.

The invention relates to a non-human mammal animal model of neurological and psychiatric diseases and a preparation method and application thereof. A mouse model provided by the invention is in high similarity with the model of human neurological and psychiatric diseases. A neurological and psychiatric diseases drug screening platform based on the animal model can be used in new drug screening and development of other treatments.

The present invention provides a method for modulating or regulating levels of a neurochemical in an individual using deep brain stimulation. More particularly, the invention relates to a method of treating neurological and psychiatric diseases by providing a feedback loop capable of maintaining central and/or peripheral nervous system neurochemical levels in an individual.

A method of diagnosing depression in a subject, comprising analyzing a biological sample from a subject in need of diagnosis of depression for the expression of spadin, detecting and measuring the amount of spadin in the sample, and diagnosing depression in the subject if an increase or a decrease in spadin expression in the biological sample is detected compared to a control, is described as are methods for monitoring treatment, remission and the course of the disease. Related kits are also described. Also described is a method for identifying candidate compounds for treating depression.

The present invention relates to a novel class of substituted phenylpiperazinyl derivatives having the formula (I) wherein X, Z, Y, U,V, Alk, W, R<1> , R<2>, R<3>, R<11>, R<12>, R<13> n, m and the dotted line are as defined in the description. The compounds of the invention are dopamine D4 receptor ligands and are therefore useful for the treatment of certain psychiatric and neurologic disorders, including psychosis.

The present invention provides a method for identifying a compound or a combination of compounds having a pharmacological behavior that qualifies it as a candidate for clinical development of a drug for treatment of a psychiatric disease or disorder, preferably schizophrenia. According to this method, a candidate drug is assessed for its ability to produce a biochemical profile, in either or both in vitro and in vivo test systems, which is similar to a unique reference biochemical profile obtained following treatments with drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.

The invention discloses a psychiatric disease auxiliary diagnosis system based on virtual reality technology and physiological parameter detection. The system comprises a patient terminal device and adoctor terminal device; the patient terminal device comprises a physiological parameter monitoring module, a VR/AR interaction module and a data acquisition and processing module; the VR/AR interaction module induces a user to generate special behaviors and mood fluctuations by displaying specific scenes to the user; the physiological parameter monitoring module is used for acquiring various physiological parameter data of the user in real time; acquired data are transmitted to the doctor terminal device through the Internet; the doctor terminal device includes a real scene acquisition module, a communication and control module, a tracking module and a display module, wherein the display module displays various indicators and behavior interaction modes of the user; and therefore, auxiliary diagnosis can be completed. According to the system, the VR/AR technology and physiological parameter monitoring are combined, and therefore, diagnostic accuracy can be improved, and the preventionand early treatment of psychiatric diseases can be benefitted.

The present invention provides a method for identifying an agent to be tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical anti-psychotic activity, comprising contacting cells or tissues with a candidate drug, determining levels of phosphorylation of the intracellular signaling proteins, DARPP-32, ERK1, ERK2 and CREB, in said cells or tissues and determining the pattern of the levels of phosphorylation of the proteins. The pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB is, in certain embodiments, compared with the pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB in the presence of an atypical anti-psychotic drug.

The invention belongs to the field of neurological and psychiatric gene detection and particularly relates to a high-throughout sequencing method of genes relative to neurological and psychiatric drugs and application of the high-throughout sequencing method. The invention provides the high-throughout sequencing method of the genes relative to the neurological and psychiatric drugs and the application of the high-throughout sequencing method. The method comprises the following steps of acquisition of a genome DNA, target gene multiplex PCR amplification reaction and product purification, linker sequence PCR reaction and product purification, library detection, high-throughout sequencing and the like. The method can be used for detecting 29 SNP loci of 20 genes relative to drugs for neurological and psychiatric diseases at one time, can cover a vast majority of first-line and second-line drugs for resisting schizophrenia, depression, anxiety, epilepsy, Parkinson's disease, hyperkineticdisorder, pains and the like and provides guidance to medication of a patient to the maximum.

The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.

Methods and compositions relate to genetic markers of psychotic disorders, e.g., schizophrenia (SZ), are provided. For example, in certain aspects methods for determinations of a SULT4A1-1 haplotype are described. Furthermore, the invention provides methods and compositions involving treatment of psychotic disorders using the haplotype status.

Deep Brain Stimulation (DBS) is taking off and will be part of the main treatment for brain diseases such as movement disorders, epilepsy, psychiatric diseases and many others. There is a need for more sophisticated devices that can do more in one penetration, not just stimulate. Once there is a probe in the brain, it is used for multiple passive measurements, without harming the brain further. It provides better understanding the brain and real time closed loop improved treatment. An apparatus and method are disclosed, which allow simultaneous monitoring of multiple parameters inside the human brain, such as: pH, temperature, pressure, seizure activity (EEG), degree of metabolism, oxygen tension in the brain, degree of excitotoxicity and others. The ability to measure those parameters during treatment and stimulation procedures makes the difference between success and failure of the patient.